BioMed Research International

BioMed Research International / 2021 / Article

Research Article | Open Access

Volume 2021 |Article ID 7389076 | https://doi.org/10.1155/2021/7389076

Baye Dagnew, Yigizie Yeshaw, Demeke Geremew, Dessie Abebaw Angaw, Henok Dagne, Mekuriaw Alemayehu, Meseret Derbew Molla, Yonas Akalu, "Hypertriglyceridemia and Other Plasma Lipid Profile Abnormalities among People Living with Diabetes Mellitus in Ethiopia: A Systematic Review and Meta-Analysis", BioMed Research International, vol. 2021, Article ID 7389076, 12 pages, 2021. https://doi.org/10.1155/2021/7389076

Hypertriglyceridemia and Other Plasma Lipid Profile Abnormalities among People Living with Diabetes Mellitus in Ethiopia: A Systematic Review and Meta-Analysis

Academic Editor: Carlos R. Bueno Junior
Received03 Aug 2020
Revised11 Mar 2021
Accepted30 Apr 2021
Published11 May 2021

Abstract

Background. Dyslipidemia is one of the leading causes of cardiovascular complications in diabetes mellitus (DM) patients. Though it is a major public health problem in Ethiopia, there is no a nation-wide study to determine dyslipidemia among DM patients yet. Therefore, this systematic review and meta-analysis intended to estimate the prevalence of hypertriglyceridemia and other plasma lipid abnormalities among people living with DM in Ethiopia. Methods. We systematically searched PubMed, Google Scholar, African Journals Online, Hinari, and direct Google. Studies conducted until May 9, 2020, that reports the prevalence of dyslipidemia among people living with DM were included. The DerSimonian and Laird random-effects model was used to determine the pooled prevalence of lipid profile abnormalities. Heterogeneity was checked using the statistic, whereas publication bias was tested by funnel plot and Egger’s test. Besides, subgroup and sensitivity analyses were performed. Results. We used 18 primary studies, including 4961 participants living with DM, which met the eligibility criteria for the meta-analysis of hypertriglyceridemia. The estimate of hypertriglyceridemia (≥150 mg/dl) was 48.15% (95% CI: 38.15-58.15, ) after performing the main meta-analysis using the random-effects model. The subgroup analysis showed a higher pooled estimate of hypertriglyceridemia among T2DM (57.80% (95% CI: 50.50-65.10), ), studies that used probability sampling technique (59.09% (95% CI: 43.58-74.59), , ), and studies from primary data sources (51.43% (95% CI: 40.72-62.13), , ). Moreover, the estimated pooled prevalence of the total plasma cholesterol () was 34.08% (95% CI: 28.41-39.75, ), was 41.13% (95% CI: 27.15-55.11, I2 = 98.8%), and was 44.36% (95% CI: 31.82-56.90, ). Conclusions. The pooled prevalence of hypertriglyceridemia and other lipid abnormalities among DM patients was relatively high in Ethiopia. It strongly suggests the need to give maximal attention to the adherence of DM management to reduce the circulatory lipid profile abnormalities and subsequent complications. Prospero Registration. CRD42020182291.

1. Background

Dyslipidemia is a derangement of lipoprotein metabolism characterized by an increased level of serum triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and decreased level of high-density lipoprotein cholesterol (HDL-C) [1]. It is a risk factor for cardiovascular diseases (CVDs) [2, 3]. Acquired dyslipidemia is caused by sedentary lifestyle such as an unhealthy diet and chronic illnesses such as obesity, chronic kidney disease, hepatic diseases, and DM [46]. In return, dyslipidemia contributes to the occurrence of CVDs in DM patients [7].

Dyslipidemia in DM patients is largely attributed to both increased production and delayed catabolism of very-low-density lipoprotein (VLDL) secondary to resistance and a relative deficiency of insulin, a key hormone that regulates lipid metabolism [3, 8]. Physiologically, insulin reduces VLDL production by inhibiting the activation of hormone-sensitive lipase at adipose tissue and decreases the circulating nonesterified free fatty acids from adipocytes. Thus, the production of nascent VLDL and apoprotein B100 (Apo B100) is inhibited because of limited free fatty acids in the circulation [9]. Increased hepatic lipogenesis also increases liver cholesterol [10]. Besides, insulin activates lipoprotein lipase (LPL) which metabolizes circulatory triglyceride and VLDL to free fatty acid and glycerol and also increases the expression of LDL receptors to facilitate the uptake of VLDL remnants by the tissues [3]. In DM patients, low, absence, or insulin resistance results in a rise of triglyceride and VLDL. The normal inhibitory effect of insulin on hepatic Apo B100 production and triglyceride secretion is lost, and the secreted VLDL becomes higher than utilization [11]. Insulin resistance causes loss of potent stimulatory effect of insulin on LPL and contributes to the increment of triglyceride in the plasma [12, 13]. Stimulation of LDL clearance via increasing LDL-C receptor expression and activity by insulin is also lost because of insulin resistance [3].

Diabetes mellitus is associated with vascular problems such as peripheral arterial disease [14] and hypertension [15]. Hypertriglyceridemia combined with low HDL-C or high LDL-C in DM populations contributes to life-threatening vascular complications [8, 16, 17] including ischemic stroke [18, 19]. Besides the morbidity and mortality, hypertriglyceridemia increases the health care costs of people living with DM [20].

Evidences revealed that poor nutritional knowledge, inadequate dietary practice, low level of physical activity [21], obesity [21, 22], poor glycemic control [23], being hypertensive [2123], old age [21, 22], low education status [21], and duration of DM [22, 23] were significant predictors of dyslipidemia among people living with DM.

Globally, dyslipidemia causes around 2.6 million deaths and 29.7 million disability-adjusted life years (DALYs) [24, 25]. The prevalence of dyslipidemia, among DM patients, is 67.1% in China [26], 86% in Bangladesh [27], 88.9% in Thailand [28], and 89% in India [29] whereas, in Ethiopia, hypertriglyceridemia ranges from 14.2% [30] to 72.5% [31]. Apt management is essential [32] which is expensive in resource-limited settings like Ethiopia. Hence, measuring the prevalence and directing this scarce resource towards its prevention is the best solution. There is no comprehensive study conducted in Ethiopia to determine triglyceridemia and other plasma lipid profile abnormalities among people living with DM. Therefore, this meta-analysis intended to determine the pooled prevalence of dyslipidemia (high TG, low HDL-C, high LDL-C, and high TC) among people living with DM in Ethiopia.

2. Methods

2.1. Reporting and Registration

We conducted this systematic review and meta-analysis based on the principles of the Centre for Reviews and Dissemination’s (CRD) guidance for undertaking reviews in health care [33], and the reporting system was following the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) [34]. It is registered at Prospero with an identification number CRD42020182291 available at https://www.crd.york.ac.uk/prospero/#myprospero.

2.2. Data Sources

Major electronic databases (PubMed, Hinari, African Journals Online, and Google Scholar) were used to access relevant studies. Besides, a direct Google search was used to repossess a few articles after looking at the reference lists of included studies to account for the omission of the studies during searching of electronic databases. To account for unpublished data, we used the institutional repository of Addis Ababa University.

2.3. Searching Strategy

All pocket/primary studies reporting proportion or prevalence of hypertriglyceridemia and/or other plasma lipid abnormalities (abnormally high TC, high LDL-C, and low HDL-C), among people living with either T1DM or T2DM in Ethiopia, were the targets for this review. After identifying entry terms using the MeSH (medical subject heading) browser, relevant terms or phrases were combined using Boolean operators “OR” and “AND” to fit the advanced search by considering the CoCoPo (condition, context, population) principle. We used (“Dyslipidemia” [Title/Abstract] OR “Metabolic syndrome” [Title/Abstract]) OR “Dyslipidaemia” [Title/Abstract]) OR “Dyslipoproteinemias” [Title/Abstract]) OR “Hyperlipidemia” [Title/Abstract]) OR “high total Cholesterol” [Title/Abstract]) OR “high Triglycerides” [Title/Abstract]) OR “low ‘High Density Lipoprotein Cholesterol’” [Title/Abstract]) OR “elevated Low Density Lipoprotein Cholesterol’” [Title/Abstract]) AND “Diabetes mellitus” [Title/Abstract]) OR “Hyperglycemia” [Title/Abstract]) OR “Diabetes” [Title/Abstract]) AND “Ethiopia” [Title/Abstract] for searching articles in PubMed. We also used advanced searches for other databases.

2.4. Eligibility Criteria
2.4.1. Inclusion Criteria

Population: people living with either T1DM or T2DM.

Setting: pocket studies conducted in Ethiopia or any localities of the country.

The outcome of interest: hypertriglyceridemia and other plasma lipid abnormalities (dyslipidemia) among people living with DM.

Study design types: observational studies (cross-sectional or case-control studies) reporting the prevalence or proportion of people with abnormal plasma lipid concentration.

Publication status: both published and unpublished studies were included.

Publication language: English.

Publication date: published until 9 May 2020.

2.5. Exclusion Criteria

Case-reports, case-series, letters to the journal editors, communications, and studies conducted on specific population were excluded.

2.6. Study Selection

Three independent authors (BD, DG, and YY) identified articles using electronic databases and other sources. All studies were exported from data sources into Endnote X7 for duplicate removal and citation. Two reviewers (BD and YY) selected relevant studies after evaluating title, abstract, and then full-text review for the abstraction of the data by using inclusion criteria. These reviewers harmonized most disagreements after discussion, and the third reviewer (DG) took part to resolve a few divergences between the two reviewers (BD and YY).

2.7. Quality Assessment of Included Studies

Two authors (HD and YA) investigated the quality of included studies using a modified Hoy et al. quality assessment tool [35]. This tool has 9 risks of bias items (each comprises zero or one risk of bias points) which have a maximum score of “9” and a minimum score of “0.” Ranking of risk of bias is labelled as low risk (0-3), moderate risk (4–6), and finally high risk (7–9). The third reviewer (MA) synchronized differences in quality appraisal between the two authors (HD and YA).

2.8. Data Abstraction

Structured data extraction sheet was prepared by two authors (HD and DAA) using Microsoft Excel 2010. The template of data extraction format contained the name of the primary author, publication year of the study, study design, regional state of the study, sample size, actual number of cases with specific plasma lipid abnormality, and percentage of individuals with specific lipid abnormality. Then, two authors (BD and YY) extracted the relevant data independently, and the extracted data of the two authors (BD and YY) were compared. Discrepancies were resolved by consensus after discussion.

2.9. Outcome Measurement

We used hypertriglyceridemia and other plasma lipid abnormalities as outcome variables. In the primary studies, the outcome variables were obtained by biochemical tests after drawing blood from each participant. Dyslipidemia is defined based on National Cholesterol Education Program Adult Treatment Panel III guideline which comprised either single or a combination of plasma lipid abnormalities. The following criteria were used for the diagnosis of overall dyslipidemia, i.e., , , , and [36].

2.10. Statistical Analysis

Endnote X7 and Stata 11 were used for bibliographical management and statistical analysis, respectively. Heterogeneity was tested using the statistic, and test was used to identify possible interstudy variations. The values 25%, 50%, and 75% denote low, moderate, and high heterogeneity, respectively [37]. We used the DerSimonian and Laird random-effects model [38] for the main meta-analysis of the pooled estimates of the prevalence of hypertriglyceridemia and other plasma lipid abnormalities. Subgroup analysis was considered to account for possible heterogeneity. Publication bias (using the Funnel plot and Egger’s test) [39], trim and fill [40], and sensitivity analyses were performed. For each plasma lipid abnormality, the point estimate was shown by the forest plot.

3. Results

3.1. The Review Process and Characteristics of the Included Studies

Eighteen primary studies (with 4961 participants living with either T1DM or T2DM) [22, 30, 31, 4155] that met the inclusion criteria for the meta-analysis of hypertriglyceridemia were analyzed (Figure 1). Sixteen studies [22, 30, 31, 4145, 4751, 5355] were published from 2003 to 2019, and only two studies were unpublished [46, 52]. A sample size of included studies ranged from 77 [47] to 581 [48]. Most studies were conducted in Addis Ababa [30, 43, 46, 48, 50, 52], and one study in Oromia region [47] (Table 1).


AuthorYearStudy regionStudy designType of DMSample size () (%) () (%) () (%) () (%)Quality status

Seyoum B [30]2003Addis AbabaCSMixed3025618.54314.2Low risk
E.S. Siraj [50]2006Addis AbabaCSMixed1466947.36141.86645.28457.5Low risk
Belay Z [43]2014Addis AbabaCCT2DM803948.84758.86277.55265.0Low risk
Melaku S [48]2015Addis AbabaCSMixed58111620.011319.4457.7376.4Low risk
Ambachew [42]2015SNNPCSMixed29510234.68829.818863.73612.2Low risk
Bekele S [22]2017SNNPCSMixed2245323.79140.69843.89442.0Low risk
Tadewos A [51]2017SNNPCST2DM27018468.112747.0Low risk
Woyesa [54]2017SNNPCST2DM31422170.412339.2Low risk
Mideksa S [49]2018TigrayCSMixed3367622.615445.86218.514442.9Low risk
Belete B [44]2018AmharaCST2DM1598251.69962.39257.95031.4Low risk
Birara [45]2018AmharaCST2DM25617367.617166.8Low risk
Wolde HF [53]2018AmharaCST2DM34113038.116347.815545.510731.4Low risk
Abera MA [41]2019TigrayCSMixed42112229.0Low risk
Mamo Y [47]2019OromiaCCT2DM773241.63140.32431.22937.7Low risk
Fasil A [31]2019AmharaCSMixed36712233.226672.5Low risk
Wube TB [55]2019SNNPCST2DM31410332.822170.44514.319160.8Low risk
Bethelhem T [52]2015Addis AbabaCST2DM1064138.74340.65249.18075.5Low risk
Birle M [46]2019Addis AbabaCST2DM37217847.819151.3Low risk

Studies not published, but the showed year depicts the study period. CS: cross-sectional; CC: case-control.
3.2. The Pooled Prevalence of Hypertriglyceridemia among People Living with DM

In the fixed-effects model analysis, the pooled prevalence of hypertriglyceridemia was 43.9% (95% CI: 42.65-45.16%, ) with substantial interstudy variation (heterogeneity). To account for this, we performed the main meta-analysis using the DerSimonian and Laird random-effects model to determine the pooled prevalence of hypertriglyceridemia, and it was 48.15% (95% CI: 38.15-58.15) (Figure 2).

3.3. Other Dyslipidemia among People Living with DM in Ethiopia

Thirteen studies (3328 participants) were eligible for the estimation of the prevalence of total cholesterolemia among people living with DM. After running the main meta-analysis using the random-effects model, the pooled prevalence of high TC was 34.08% () (Figure 3). Eleven primary studies (2659 participants) were included for the meta-analysis of elevated “LDL-C” with the prevalence of 41.13% () (Figure 4). Finally, fifteen studies (3871 participants) were eligible for meta-analysis of low “HDL-C,” and the pooled prevalence was 44.36% () (Figure 5).

3.4. Subgroup Analysis of the Pooled Prevalence of Hypertriglyceridemia

As one of the handling mechanisms of heterogeneity, we performed subgroup analysis for the pooled prevalence of hypertriglyceridemia by the type of DM, study design, sampling technique, data source, and publication status. Random-effects analysis showed a 57.80% (9% CI: 50.50-65.10) prevalence of hypertriglyceridemia among T2DM patients whereas 48.64% of the pooled prevalence was observed among published studies (Table 2).


Subgroup analysis byCharacteristicsDegree of freedomD+L pooled estimate with 95% CI ( value)

Type of DMT2DM957.80 (50.50-65.10)92.5% ()
Mixed736.60 (22.79-50.41)98.5% ()
Publication statusPublished1548.64 (37.55-59.72)98.6% ()
Unpublished145.31 (38.51-52.11)44.5% ()
Study designCase-control148.15 (38.15-58.15)82.0% ()
Cross-sectional1547.99 (37.27-58.71)98.6% ()
Sampling techniqueProbability859.09 (43.58-74.59)98.6% ()
Nonprobability637.80 (27.82-47.79)95.6% ()
Unknown134.00 (22.75-45.26)79.4% ()
Data sourcePrimary1451.43 (40.72-62.13)98.0% ()
Secondary231.96 (16.50-47.41)97.5% ()

3.5. Metaregression

We applied metaregression to identify the source of heterogeneity. Metaregression was performed using a type of DM used as population interest, sampling procedure, data source, study design, and publication status of the included studies. Of these, only a type of DM was picked as a source of heterogeneity () (Table 3).


LogitpCoef.Std. Err.95% CI
Lower limitUpper limit

Data source-.8223736.4131817-1.990.070-1.722619.077872
Sampling procedure.1127625.24994270.450.660-.4318159.6573409
Study design.707935.5331111.330.209-.45361411.869484
Type of DM1.086432.35858283.030.010.30514721.867717
Publication status-.9690825.5086497-1.910.081-2.077335.13917
_cons-1.2780571.297495-0.990.344-4.1050561.548942

3.6. Publication Bias

As indicated by the funnel plot (Figure 6), there was an asymmetrical distribution of studies which is an evidence for publication bias. However, when we performed objective publication bias (egger) test, the bias coefficient of Egger’s test was 1.255 () that indicates absence of publication bias in our study.

3.7. Sensitivity Analysis

The leave-one-out method was used to identify a significant single study effect on the combined estimate. As shown in Table 4, no study exerted a significant effect on the overall pooled prevalence of hypertriglyceridemia among people living with DM.


Study omittedEstimate(95% CI)
Lower limitUpper limit

Seyoum B (2003)50.1840.6259.74
E.S. Siraj (2006)48.5238.0958.96
Belay Z (2014)47.5537.2357.88
Melaku S (2015)49.8740.2059.55
Ambachew (2015)49.2438.7559.73
Bekele S (2017)48.5938.0859.11
Tadewos A (2017)46.9736.7657.17
Woyesa (2017)46.8336.7556.91
Mideksa S (2018)48.2937.6758.91
Belete B (2018)47.3336.9957.67
Birara (2018)47.0036.7757.23
Wolde HF (2018)48.1737.5658.79
Abera MA (2019)49.2938.7759.83
Mamo Y (2019)48.5938.2458.96
Fasil A (2019)46.6936.8256.58
Wube TB (2019)46.8336.7556.91
Bethelhem T (2015)48.5938.1958.98
Birle M (2019)48.1737.5358.81
Combined48.1538.1558.15

Studies not published, but the indicated year depicts the study conduction period.

4. Discussion

Dyslipidemia is one of the leading causes of cardiovascular diseases [56]. Given its public health significance, scholars conducted many pocket studies in different populations. However, there is no comprehensive study in Ethiopia. The main aim of the current systematic review and meta-analysis was to describe the pooled prevalence of plasma lipid abnormalities (TG, TC, LDL-C, and HDL-C) among people living with DM in Ethiopia. Accordingly, the pooled prevalence was 48.15% for TG, 34.08% for TC, 41.13% for LDL-C, and 44.36% for HDL-C. This indicates a presence of a huge number of individuals with dyslipidemia in Ethiopia, which necessitates the health sector stakeholders to design and implement preventive strategies for plasma lipid abnormalities and hence minimizing dyslipidemia-associated complications of DM and improving their quality of life.

In this meta-analysis, we found a substantial interstudy variation anticipated to affect the pooled prevalence of hypertriglyceridemia and other plasma lipid abnormalities. For the sake of handling the heterogeneity, we used random-effects model analysis for the final combined prevalence of each outcome variable. Even after running the main meta-analysis using the random-effects analysis, there was heterogeneity. Besides, subgroup analysis was executed using type of DM, study design, sampling technique, data source, and publication status.

The prevalence of hypertriglyceridemia among T2DM was 57.8% which is similar with studies in Tanzania (53.8%) [57] and India (56.1%) [58] but lower than that in a finding in Jordan (83.1%) [59]. The pooled prevalence was 48.64% among the published studies which is similar with the overall pooled prevalence of the current study (48.15%). Furthermore, metaregression was performed to sort out the real cause of heterogeneity from which the type of DM was significant source of heterogeneity.

In the current study, the pooled prevalence of hypertriglyceridemia among DM patients was 48.15%. This higher percentage could be related with the defects of insulin action [60, 61], in that low insulin or insulin resistance leads to reduced fatty acid mobilization into cells and increases lipolysis, both of which contributed to high plasma lipid levels [62]. Other studies in in Thailand (49.94%) [28], Botswana (38.9%) [63], Tanzania (53.8%) [57], India (56.1%) [58], Brazil (46.7%) [64], and Yemen (39.2%) [65] also reported similar findings. However, the pooled prevalence of hypertriglyceridemia, in this study, is lower than a finding of the local study in Jordan (83.1%) [59]. This difference might be due to the variations in the study setting and population characteristics. In contrary to this, our study finding is higher than other reports in the United States (30%) [66], Saudi Arabia (17%) [67], China (22.3%) [68], and Korea (28.7%) [69]. The reason for this might emanate from the differences in sample size, treatment options, adherence to self-care, and duration of DM.

In this review, the pooled prevalence of plasma TC was 34.08% which is in line with findings in Botswana (33.5%) [63] and India (36.3%) [58]. However, it is lower than a country-based study in Thailand (35.05%) [28] and local studies in Tanzania (49.6%) [57], Yemen (52.5%) [65], and Jordan (77.2%) [59]. This disagreement might be explained by the differences in the study population in which our study included both type 1 and 2 DM patients, whereas other studies included only people living with T2DM. It is known that people living with T2DM are more prone to plasma lipid abnormalities than T1DM [70]. It can also be due to the differences in the duration of DM, sample size, and treatment adherence. However, the current estimate of TC is higher than nation-wide studies in China [68], another study in China (6.9%) [71], Saudi Arabia (13.8%) [67], and Korea (14.5%) [69]. This might be due to lifestyle and socioeconomic differences between the study populations.

The pooled prevalence of high LDL-C was 41.13%, which is akin to an evidence in the United States (53%) [66]. However, LDL-C in our study is lower than other studies in Thailand (56.54%) [28], Tanzania (72.3%) [57], India (57.3%) [58], Brazil (79%) [64], Yemen (67.5%) [65], and Jordan (91.5%) [59]. The reason for the lower estimated high LDL-C in our review could be due to variations in sample size and scope of the study. However, the estimate of elevated LDL-C is higher than that of other studies in China [68], Saudi Arabia (12.85) [67], and Korea (14.8%) [69]. This could be due to variations in the number of participants, self-management, and duration of DM.

Finally, we estimated the prevalence of abnormally low HDL-C (44.36%) among people living with DM which is in line with other nation-wide studies in Saudi Arabia (40%) [67], Korea (41.2%) [69], and China (40.8%) [68] and local studies in India (35.7%) [58] and Brazil (34.9%) [64]. The estimate of low HDL-C is higher than studies in the United States (23%) [66] and Yemen (25.5%) [65]. This might be due to differences in the knowledge level of participants, self-care practice, and case definition used in each study. Participants in the United States are more likely to have better self-care practice. Our review finding is lower than studies conducted in Thailand (59.59%) [28], Jordan (83.9%) [59], and Tanzania (63%) [57]. This difference could be due to variations in the study population, socioeconomic status, and duration of DM.

As stated, this meta-analysis focused on pooling the prevalence of hypertriglyceridemia and other lipid abnormalities due to lack of studies which reported associated factors of dyslipidemia. In other studies, dyslipidemia is associated with increased age, urbanization, female sex, higher glucose level, smoking, and hypertension [72, 73], all of which are modifiable. The findings of this review suggest a need for comprehensive strategies to prevent plasma lipid abnormalities so that dyslipidemia-associated metabolic complications of DM can be avoided by focusing on modifiable risk factors such as lifestyle changes to achieve standard targets. In addition to this, we recommend researchers to conduct a study on determinant factors of dyslipidemia among DM patients so that strategies will be built by targeting modifiable risk factors.

4.1. Limitations of the Study

This review was the first in its kind on this topic and conducted with a robust contribution of different disciplines. However, the finding of this study should be interpreted with the following limitations. Firstly, the total participants included were not a representative of the national figure which might be difficult to generalize. But, it can be used as a good finding than other primary studies since it was a pooled prevalence of others. Secondly, there was high heterogeneity. We performed the random-effects, subgroup analysis, and metaregression to chase for the real cause of the variation, and a type of DM was the cause for heterogeneity. Thirdly, there was lack of studies in certain regions of the country and each year which might be difficult to use the results as a baseline in those regions. Finally, the included studies lack associated factors of dyslipidemia that impeded us to analyze the pooled effect of individual factors on plasma lipid abnormalities.

5. Conclusions

Our systematic review and meta-analysis revealed a high estimated prevalence of plasma lipid abnormalities, particularly TG among people living with DM. Patients need to adhere to both nonpharmacologic and pharmacologic therapies to reduce abnormal plasma lipid levels and prevent dyslipidemia-associated health risks of DM. Opportunistic test strategies to dyslipidemia parameters have to be strictly followed by all people living with DM at follow-up clinics.

Abbreviations

CI:Confidence interval
HDL-C:High-density lipoprotein cholesterol
LDL-C:Low-density lipoprotein cholesterol
TC:Total cholesterol
T1DM:Type 1 diabetes mellitus
T2DM:Type 2 diabetes mellitus.

Data Availability

Dataset can be accessed from the corresponding author upon reasonable request.

Conflicts of Interest

All authors declared that there is no competing interest.

Authors’ Contributions

Conceptualization was done by BD, YA, YY, and MDM. Data curation was performed by BD, DAA, and MA. Formal analysis was performed by BD. Investigation was performed by BD and HD. Methodology was done by BD and DAA. Resources were acquired by YA. Software was operated by BD, DAA, and MA. Validation was performed by BD, YY, HD, and DG. Writing original draft was performed by BD, MDM, YA, YY, HD, and DG. Writing review and editing were performed by BD, MDM, YA, YY, HD, DG, MA, and DAA. All authors read and approve the manuscript.

Acknowledgments

We are very grateful to Mr. Berhanu Mengistu (Researcher of Human Nutrition, University of Gondar) for his unreserved scientific comments on the revised manuscript from which our manuscript get improved. Besides, we also like to extend our gratitude to the authors of primary studies that we included in our review.

References

  1. A. D. Mooradian, “Dyslipidemia in type 2 diabetes mellitus,” Nature clinical practice Endocrinology & metabolism, vol. 5, no. 3, pp. 150–159, 2009. View at: Publisher Site | Google Scholar
  2. M. Houston, “The role of noninvasive cardiovascular testing, applied clinical nutrition and nutritional supplements in the prevention and treatment of coronary heart disease,” Therapeutic Advances in Cardiovascular Disease, vol. 12, no. 3, pp. 85–108, 2018. View at: Google Scholar
  3. B. Vergès, “Pathophysiology of diabetic dyslipidaemia: where are we?” Diabetologia, vol. 58, no. 5, pp. 886–899, 2015. View at: Publisher Site | Google Scholar
  4. D. Vodnala, M. Rubenfire, and R. D. Brook, “Secondary causes of dyslipidemia,” The American journal of cardiology, vol. 110, no. 6, pp. 823–825, 2012. View at: Publisher Site | Google Scholar
  5. M. Senoo, A. Tone, Y. Imai et al., “Marked hypertriglyceridemia in a patient with type 2 diabetes receiving SGLT2 inhibitors,” Acta Medica Okayama, vol. 75, no. 1, pp. 103–107, 2021. View at: Publisher Site | Google Scholar
  6. X. Sun, M. Feng, L. Lu et al., “Lipid abnormalities in patients with Cushing’s disease and its relationship with impaired glucose metabolism,” Frontiers in endocrinology, vol. 11, 2021. View at: Publisher Site | Google Scholar
  7. J. L. Jin, Y. X. Cao, L. G. Wu et al., “Atherogenic dyslipidaemia and cardiovascular events in patients with diabetes or pre-diabetes and stable coronary artery disease: a prospective, cohort study,” BMJ Open, vol. 11, no. 1, article e037340, 2021. View at: Publisher Site | Google Scholar
  8. R. M. Krauss, “Lipids and lipoproteins in patients with type 2 diabetes,” Diabetes Care, vol. 27, no. 6, pp. 1496–1504, 2004. View at: Publisher Site | Google Scholar
  9. N. Karimian Pour and K. Adeli, “Insulin silences apolipoprotein B mRNA translation by inducing intracellular traffic into cytoplasmic RNA granules,” Biochemistry, vol. 50, no. 32, pp. 6942–6950, 2011. View at: Publisher Site | Google Scholar
  10. J. M. Berger and Y. A. Moon, “Increased hepatic lipogenesis elevates liver cholesterol content,” Molecules and Cells, vol. 44, no. 2, pp. 116–125, 2021. View at: Publisher Site | Google Scholar
  11. J. D. Schofield, Y. Liu, P. Rao-Balakrishna, R. A. Malik, and H. Soran, “Diabetes dyslipidemia,” Diabetes therapy, vol. 7, no. 2, pp. 203–219, 2016. View at: Publisher Site | Google Scholar
  12. K. Cianflone, S. Paglialunga, and C. Roy, “Intestinally derived lipids: metabolic regulation and consequences--an overview,” Atherosclerosis Supplements, vol. 9, no. 2, pp. 63–68, 2008. View at: Publisher Site | Google Scholar
  13. I. J. Goldberg, “Clinical review 124: diabetic dyslipidemia: causes and consequences,” The Journal of clinical endocrinology and metabolism., vol. 86, no. 3, pp. 965–971, 2001. View at: Publisher Site | Google Scholar
  14. Y. Akalu and A. Birhan, “Peripheral arterial disease and its associated factors among type 2 diabetes mellitus patients at Debre Tabor general hospital, Northwest Ethiopia,” Journal of diabetes research, vol. 2020, Article ID 9419413, 9 pages, 2020. View at: Publisher Site | Google Scholar
  15. B. Dagnew and Y. Yeshaw, “Predictors of isolated systolic hypertension among type 2 diabetes mellitus patients in Jimma University Specialized Hospital, Southwest Ethiopia,” BMC Research Notes, vol. 12, no. 1, p. 510, 2019. View at: Publisher Site | Google Scholar
  16. K. Tsubakio-Yamamoto, F. Matsuura, M. Koseki et al., “Adiponectin prevents atherosclerosis by increasing cholesterol efflux from macrophages,” Biochemical and biophysical research communications, vol. 375, no. 3, pp. 390–394, 2008. View at: Publisher Site | Google Scholar
  17. B. Vergès, J. M. Petit, L. Duvillard, G. Dautin, E. Florentin, F. Galland et al., “Adiponectin is an important determinant of apoA-I catabolism,” Arteriosclerosis, thrombosis, and vascular biology, vol. 26, no. 6, pp. 1364–1369, 2006. View at: Publisher Site | Google Scholar
  18. A. L. Catapano, I. Graham, G. De Backer et al., “2016 ESC/EAS Guidelines for the Management of Dyslipidaemias,” European heart journal, vol. 37, no. 39, pp. 2999–3058, 2016. View at: Publisher Site | Google Scholar
  19. J. M. Chehade, M. Gladysz, and A. D. Mooradian, “Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management,” Drugs, vol. 73, no. 4, pp. 327–339, 2013. View at: Publisher Site | Google Scholar
  20. B. C. Case, A. P. Bress, P. Kolm et al., “The economic burden of hypertriglyceridemia among US adults with diabetes or atherosclerotic cardiovascular disease on statin therapy,” Journal of clinical lipidology, vol. 13, no. 5, pp. 754–761, 2019. View at: Publisher Site | Google Scholar
  21. K. Haile and A. Timerga, “Dyslipidemia and its associated risk factors among adult type-2 diabetic patients at Jimma University Medical Center, Jimma, Southwest Ethiopia,” Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, vol. 13, pp. 4589–4597, 2020. View at: Publisher Site | Google Scholar
  22. S. Bekele, T. Yohannes, and A. E. Mohammed, “Dyslipidemia and associated factors among diabetic patients attending Durame general Hospital in Southern Nations, nationalities, and people’s region,” Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, vol. 10, 2017. View at: Publisher Site | Google Scholar
  23. M. N. Karim, K. R. Ahmed, M. S. Bukht et al., “Pattern and predictors of dyslipidemia in patients with type 2 diabetes mellitus,” Diabetes & Metabolic Syndrome: Clinical Research & Reviews, vol. 7, no. 2, pp. 95–100, 2013. View at: Publisher Site | Google Scholar
  24. WHO, “Global Health Observatory (GHO) data, Mean cholesterol Situation and trends,” 2020, https://www.who.int/gho/ncd/risk_factors/cholesterol_mean_text/en/. View at: Google Scholar
  25. H. Wang, M. Naghavi, C. Allen et al., “Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015,” The Lancet, vol. 388, no. 10053, pp. 1459–1544, 2016. View at: Publisher Site | Google Scholar
  26. L. Yan, M. T. Xu, L. Yuan et al., “Prevalence of dyslipidemia and its control in type 2 diabetes: a multicenter study in endocrinology clinics of China,” Journal of Clinical Lipidology, vol. 10, no. 1, pp. 150–160, 2016. View at: Publisher Site | Google Scholar
  27. A. S. Bhuiyan, M. A. Bari, G. Aditya et al., “Prevalence and pattern of dyslipidemia in diabetes mellitus patients admitted in the Department of Cardiology, Mymensingh Medical College Hospital, Mymensingh, Bangladesh,” Mymensingh medical journal : MMJ, vol. 30, no. 1, pp. 21–27, 2021. View at: Google Scholar
  28. P. Narindrarangkura, W. Bosl, R. Rangsin, and P. Hatthachote, “Prevalence of dyslipidemia associated with complications in diabetic patients: a nationwide study in Thailand,” Lipids in health and disease, vol. 18, no. 1, p. 90, 2019. View at: Publisher Site | Google Scholar
  29. N. Jayarama, M. Reddy, and V. Lakshmaiah, “Prevalence and pattern of dyslipidemia in type 2 diabetes mellitus patients in a rural tertiary care centre, southern India,” Global Journal of Medicine & Public Health, vol. 1, pp. 24–28, 2012. View at: Google Scholar
  30. B. Seyoum, J. Abdulkadir, P. Berhanu et al., “Analysis of serum lipids and lipoproteins in Ethiopian diabetic patients,” Ethiopian medical journal, vol. 41, no. 1, pp. 1–8, 2003. View at: Google Scholar
  31. A. Fasil, B. Biadgo, and M. Abebe, “Glycemic control and diabetes complications among diabetes mellitus patients attending at University of Gondar Hospital, Northwest Ethiopia,” Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, vol. 12, pp. 75–83, 2019. View at: Publisher Site | Google Scholar
  32. B. Dagnew, G. D. Demissie, and D. A. Angaw, “Systematic review and meta-analysis of good self-care practice among people living with type 2 diabetes mellitus in Ethiopia: a national call to bolster lifestyle changes,” Evidence-Based Complementary and Alternative Medicine, vol. 2021, Article ID 8896896, 10 pages, 2021. View at: Publisher Site | Google Scholar
  33. C. Dissemination, CRD’s Guidance for Undertaking Reviews in Health Care, University of York, Centre for Reviews and Dissemination, Layerthorpe, 2009.
  34. K. Knobloch, U. Yoon, and P. M. Vogt, “Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias,” Journal of Cranio-Maxillofacial Surgery, vol. 39, no. 2, pp. 91-92, 2011. View at: Publisher Site | Google Scholar
  35. D. Hoy, P. Brooks, A. Woolf et al., “Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement,” Journal of clinical epidemiology, vol. 65, no. 9, pp. 934–939, 2012. View at: Publisher Site | Google Scholar
  36. J. Cleeman, S. Grundy, D. Becker, and L. Clark, “Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP III),” Journal of the American Medical Association, vol. 285, no. 19, pp. 2486–2497, 2001. View at: Google Scholar
  37. J. P. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman, “Measuring inconsistency in meta-analyses,” BMJ, vol. 327, no. 7414, pp. 557–560, 2003. View at: Publisher Site | Google Scholar
  38. R. DerSimonian and N. Laird, “Meta-analysis in clinical trials,” Controlled Clinical Trials, vol. 7, no. 3, pp. 177–188, 1986. View at: Publisher Site | Google Scholar
  39. H. R. Rothstein, A. J. Sutton, and M. Borenstein, “Publication Bias in Meta‐Analysis: Prevention, Assessment and Adjustments,” in Publication bias in meta-analysis, pp. 1–7, Elsevier, 2005. View at: Publisher Site | Google Scholar
  40. S. Duval and R. Tweedie, “Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis,” Biometrics, vol. 56, no. 2, pp. 455–463, 2000. View at: Publisher Site | Google Scholar
  41. M. A. Abera, T. Gebregziabher, H. Tesfay, and M. Alemayehu, “Factors associated with the occurrence of hypertension and dyslipidemia among diabetic patients attending the diabetes clinic of Ayder Comprehensive Specialized Hospital, Mekelle, Ethiopia,” East African Journal of Health Sciences, vol. 1, no. 1, pp. 3–16, 2019. View at: Google Scholar
  42. A. Henock, S. Techalew, and L. Kinfe, “Dyslipidemia among diabetic patients in Southern Ethiopia: cross-sectional study,” Journal of Diabetes and Endocrinology, vol. 6, no. 4, pp. 19–24, 2015. View at: Publisher Site | Google Scholar
  43. Z. Belay, S. Daniel, K. Tedla, and N. Gnanasekaran, “Impairment of liver function tests and lipid profiles in type 2 diabetic patients treated at the diabetic center in Tikur Anbessa specialized teaching hospital (Tasth), Addis Ababa, Ethiopia,” Journal of Diabetes & Metabolism, vol. 5, no. 11, 2014. View at: Publisher Site | Google Scholar
  44. B. Biadgo, T. Melak, S. Ambachew et al., “The prevalence of metabolic syndrome and its components among type 2 diabetes mellitus patients at a tertiary hospital, northwest Ethiopia,” Ethiopian journal of health sciences, vol. 28, no. 5, 2019. View at: Publisher Site | Google Scholar
  45. M. K. Birarra and D. A. Gelayee, “Metabolic syndrome among type 2 diabetic patients in Ethiopia: a cross-sectional study,” BMC cardiovascular disorders, vol. 18, no. 1, p. 149, 2018. View at: Publisher Site | Google Scholar
  46. M. Birlie, Assessment of metabolic syndrome in relation to sex among type ΙΙ diabetes mellitus patients in Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia, Addis Ababa university institutional repository, 2019, http://etd.aau.edu.et/handle/123456789/21171.
  47. Y. Mamo, F. Bekele, T. Nigussie, and A. Zewudie, “Determinants of poor glycemic control among adult patients with type 2 diabetes mellitus in Jimma University Medical Center, Jimma zone, south west Ethiopia: a case control study,” BMC endocrine disorders, vol. 19, no. 1, p. 91, 2019. View at: Publisher Site | Google Scholar
  48. S. Melaku, F. Enquselassie, and W. Shibeshi, “Assessment of glycaemic, lipid and blood pressure control among diabetic patients in Yekatit 12 Hospital, Addis Ababa, Ethiopia,” Ethiopian Pharmaceutical Journal, vol. 31, no. 2, pp. 131–140, 2016. View at: Publisher Site | Google Scholar
  49. S. Mideksa, S. Ambachew, B. Biadgo, and H. W. Baynes, “Glycemic control and its associated factors among diabetes mellitus patients at Ayder Comprehensive Specialized Hospital, Mekelle-Ethiopia,” Adipocyte, vol. 7, no. 3, pp. 197–203, 2018. View at: Publisher Site | Google Scholar
  50. E. S. Siraj, B. Seyoum, C. Saenz, and J. Abdulkadir, “Lipid and lipoprotein profiles in Ethiopian patients with diabetes mellitus,” Metabolism, vol. 55, no. 6, pp. 706–710, 2006. View at: Publisher Site | Google Scholar
  51. A. Tadewos, H. Ambachew, and D. Assegu, “Pattern of metabolic syndrome in relation to gender among type-II DM patients in Hawassa University Comprehensive Specialized Hospital, Hawassa, Southern Ethiopia,” Health Science Journal, vol. 11, no. 3, 2017. View at: Publisher Site | Google Scholar
  52. B. Tefera, Insulin Resistance and Dyslipidemia in Type 2 Diabetic Patients: a Cross-Sectional Study at the Diabetic Clinic of Tikur Anbessa Specialized Teaching Hospital, [Ph.D thesis], Addis Ababa University, 2015.
  53. H. F. Wolde, A. Atsedeweyen, A. Jember et al., “Predictors of vascular complications among type 2 diabetes mellitus patients at University of Gondar Referral Hospital: a retrospective follow-up study,” BMC endocrine disorders, vol. 18, no. 1, p. 52, 2018. View at: Publisher Site | Google Scholar
  54. S. B. Woyesa, A. T. Hirigo, and T. B. Wube, “Hyperuricemia and metabolic syndrome in type 2 diabetes mellitus patients at Hawassa university comprehensive specialized hospital, South West Ethiopia,” BMC endocrine disorders, vol. 17, no. 1, p. 76, 2017. View at: Publisher Site | Google Scholar
  55. B. W. Temesgen, A. B. Tsegaye, and T. H. Agete, “Prevalence of dyslipidemia and its correlation with anthropometric and blood pressure variables among type-2 diabetic patients,” Journal of Diabetes and Endocrinology, vol. 11, no. 1, pp. 10–17, 2020. View at: Publisher Site | Google Scholar
  56. G. A. Roth, G. A. Mensah, C. O. Johnson et al., “Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 Study,” Journal of the American College of Cardiology, vol. 76, no. 25, pp. 2982–3021, 2020. View at: Publisher Site | Google Scholar
  57. N. G. Chamba, E. R. Shao, T. Sonda, and I. A. Lyaruu, “Lipid profile of type 2 diabetic patients at a tertiary hospital in Tanzania: cross sectional study,” Journal of Endocrinology and Diabetes, vol. 4, no. 1, pp. 1–6, 2017. View at: Publisher Site | Google Scholar
  58. H. Pandya, J. Lakhani, J. Dadhania, and A. Trivedi, “The Prevalence and Pattern of Dyslipidemia among Type 2 Diabetic Patients at Rural Based Hospital in Gujarat, India,” Indian Journal of Clinical Practice, vol. 22, no. 12, pp. 640–648, 2012. View at: Google Scholar
  59. N. M. Abdel-Aal, A. T. Ahmad, E. S. Froelicher, A. M. Batieha, M. M. Hamza, and K. M. Ajlouni, “Prevalence of dyslipidemia in patients with type 2 diabetes in Jordan,” Saudi Medical Journal, vol. 29, no. 10, pp. 1423–1428, 2008. View at: Google Scholar
  60. A. Al-Mrabeh, “β-Cell dysfunction, hepatic lipid metabolism, and cardiovascular health in type 2 diabetes: new directions of research and novel therapeutic strategies,” Biomedicines, vol. 9, no. 2, 2021. View at: Publisher Site | Google Scholar
  61. I. J. Goldberg, “Diabetic dyslipidemia: causes and consequences,” The Journal of Clinical Endocrinology & Metabolism., vol. 86, no. 3, pp. 965–971, 2001. View at: Publisher Site | Google Scholar
  62. E. Otto-Buczkowska and P. Jarosz-Chobot, “Lipid metabolism. I. Role of insulin in lipid metabolism,” Polski Merkuriusz Lekarski, vol. 10, no. 57, pp. 180–184, 2001. View at: Google Scholar
  63. A. Y. Mengesha, “Lipid profile among diabetes patients in Gaborone, Botswana,” Suid-Afrikaanse tydskrif vir geneeskunde, vol. 96, no. 2, pp. 147-148, 2006. View at: Google Scholar
  64. K. Suastika, I. M. S. Semadi, I. M. P. Dwipayana et al., “Dyslipidemia in diabetes: a population-based study in Bali,” International journal of general medicine, vol. 12, pp. 313–321, 2019. View at: Publisher Site | Google Scholar
  65. A. Ghouth, A. Ba-Karman, H. Alaidroos, M. Alajely, and M. Bin-Talib, “Prevalence and patterns of dyslipidemia among type 2 Di-abetes mellitus patients in Mukalla city, Yemen, in 2017,” Community Medicine and Public Health Care, vol. 6, 2019. View at: Publisher Site | Google Scholar
  66. P. P. Tóth, D. Potter, and E. E. Ming, “Prevalence of lipid abnormalities in the united states: the national health and nutrition examination survey 2003–2006,” Journal of clinical lipidology, vol. 6, no. 4, pp. 325–330, 2012. View at: Google Scholar
  67. E. L. F. Yasser Taher Al-Hassan, E. Estrella, and M. Aatif, “Prevalence and determinants of dyslipidemia: data from a Saudi University Clinic,” The Open Public Health Journal, vol. 11, no. 1, 2018. View at: Google Scholar
  68. Y. Li, L. Zhao, D. Yu, and G. Ding, “The prevalence and risk factors of dyslipidemia in different diabetic progression stages among middle-aged and elderly populations in China,” PLoS One, vol. 13, no. 10, 2018. View at: Publisher Site | Google Scholar
  69. E. Roh, S.-H. Ko, H.-S. Kwon et al., “Prevalence and management of dyslipidemia in Korea: Korea National Health and Nutrition Examination Survey during 1998 to 2010,” Diabetes & metabolism journal, vol. 37, no. 6, pp. 433–449, 2013. View at: Publisher Site | Google Scholar
  70. K. R. Feingold and C. Grunfeld, “Diabetes and dyslipidemia,” Endotext, 2019, MDText.com, Inc. View at: Google Scholar
  71. M. Zhang, Q. Deng, L. Wang et al., “Prevalence of dyslipidemia and achievement of low-density lipoprotein cholesterol targets in Chinese adults: a nationally representative survey of 163,641 adults,” International journal of cardiology, vol. 260, pp. 196–203, 2018. View at: Publisher Site | Google Scholar
  72. S. Wang, L. Xu, J. B. Jonas, Q. S. You, Y. X. Wang, and H. Yang, “Prevalence and associated factors of dyslipidemia in the adult Chinese population,” PLoS One, vol. 6, no. 3, article e17326, 2011. View at: Publisher Site | Google Scholar
  73. L. N. Marzec and T. M. Maddox, “Medication adherence in patients with diabetes and dyslipidemia: associated factors and strategies for improvement,” Current cardiology reports, vol. 15, no. 11, p. 418, 2013. View at: Publisher Site | Google Scholar

Copyright © 2021 Baye Dagnew et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder
Views607
Downloads777
Citations

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.